Secretome Therapeutics Presentation at the Non-Dilutive Funding Summit
The 21st Non-Dilutive Funding Summit brought together hundreds of life science industry leaders with representatives from some of the leading funding agencies including ARPA-H, BARDA, CPRIT, CIRM, Breakthrough T1D and more, giving attendees the opportunity to learn more in-depth about what non-dilutive funding opportunities are available and relevant for their R&D directly from the funding agencies.
Additionally, the 2025 FreeMind Elite honorees took to the stage to present about their companies research and pipelines and their journey to securing non-dilutive funding.
This free summit is hosted by the FreeMind Group. FreeMind helps companies secure non-dilutive funding for life science R&D and wins over $100 million each year for clients. Follow us on LinkedIn or get our newsletter for news about non-dilutive funding opportunities, announcements about conferences with the best partnering, and discounts for those conferences.
Secretome Therapeutics
Secretome Therapeutics is a clinical-stage biotechnology company based in Plano, Texas, developing novel therapies derived from neonatal cardiac progenitor cells (nCPCs). Our lead product, STM-01, is a first-in-class cellular therapy designed to modulate inflammatory and fibrotic pathways and support myocardial function in dilated cardiomyopathy (DCM) and heart failure with preserved ejection fraction (HFpEF). Additionally, Secretome Therapeutics is advancing STM-21, a secretome-based therapeutic currently in preclinical development for inflammatory conditions, including skin wounds and diabetes-associated co-morbidities.
